Insider Transactions in Q3 2022 at Aprea Therapeutics, Inc. (APRE)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 23
2022
|
Marc Duey Director |
BUY
Conversion of derivative security
|
Indirect |
11,610
+95.07%
|
-
|
|
Aug 23
2022
|
Marc Duey Director |
BUY
Conversion of derivative security
|
Direct |
4,009,690
+49.03%
|
-
|
|
Aug 23
2022
|
Rifat Pamukcu Director |
BUY
Conversion of derivative security
|
Indirect |
271,870
+95.07%
|
-
|
|
Aug 23
2022
|
Rifat Pamukcu Director |
BUY
Conversion of derivative security
|
Direct |
49,280
+46.31%
|
-
|
|
Aug 23
2022
|
Oren Gilad President/CEO |
BUY
Conversion of derivative security
|
Direct |
6,045,100
+48.67%
|
-
|
|
Jul 28
2022
|
Bernd R. Seizinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+1.81%
|
-
|
|
Jul 28
2022
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,400
+11.11%
|
-
|
|
Jul 28
2022
|
Richard Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+36.11%
|
-
|
|
Jul 28
2022
|
Rifat Pamukcu Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+43.26%
|
-
|
|
Jul 28
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+34.68%
|
-
|
|
Jul 28
2022
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+27.75%
|
-
|
|
Jul 28
2022
|
Michael Grissinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+50.0%
|
-
|
|
Jul 28
2022
|
Oren Gilad President/CEO |
BUY
Grant, award, or other acquisition
|
Direct |
101,300
+23.47%
|
-
|
|
Jul 28
2022
|
Marc Duey Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+3.66%
|
-
|
|
Jul 28
2022
|
Scott M Coiante SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,800
+29.53%
|
-
|